Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bellicum Pharmaceuticals is a clinical stage company developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum's novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response.

HOUSTON, June  15, 2020  (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND) for BPX-603. BPX-603 is a GoCAR-T® product candidate targeting solid tumors that express human epidermal growth factor receptor 2 (HER2). BPX-603 is the company’s first dual-switch GoCAR-T® product candidate, which incorporates both the company’s iMC activation and CaspaCIDe® safety switch technologies.

Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors

HOUSTON, May  27, 2020  (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the publication of preclinical data from its GoCAR-NK™ Cell Program in the digital edition of Blood Advances, a journal published by The American Society of Hematology. The article is titled “Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells.”  Bellicum’s proprietary inducible MyD88/CD40 (iMC) activation switch is incorporated into its GoCAR product candidates. In this study, incorporating iMC into CAR-NK cells was found to improve cell proliferation and persistence, stimulate cytokine production, and enhance innate cytotoxicity against tumor cells in multiple models.  

Bellicum Announces Publication of Data for GoCAR-NK™ Cell Program

Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About Bellicum Pharmaceuticals (BLCM) Rating Upgrade to Strong Buy

HOUSTON, April  30, 2020  (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to one new employee consisting of an aggregate of 15,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of April 30, 2020. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Bellicum Reports Inducement  Grants Under Nasdaq Listing Rule 5635(c)(4)

Purchase price of $15 million from sale of manufacturing, office and laboratory facility

Bellicum Completes Sale of Houston Facility

Bellicum Pharmaceuticals, Inc. (BLCM) CEO Richard Fair on Q4 2019 Results - Earnings Call Transcript

Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bellicum Pharmaceuticals (BLCM) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

HOUSTON, Feb.  28, 2020  (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to one new employee consisting of an aggregate of 15,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of February 28, 2020. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Bellicum Reports Inducement - Grants Under Nasdaq Listing Rule 5635(c)(4)

HOUSTON, Feb.  05, 2020  (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) (“Bellicum” or the “Company”), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on February 5, 2020. The Company’s common stock will begin trading on a split-adjusted basis commencing upon market open on February 6, 2020.

Bellicum Announces Reverse Stock Split

HOUSTON, Jan.  31, 2020  (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Compensation Committee of the Board of Directors has approved an inducement award consisting of a stock option to purchase up to 156,000 shares of the Company’s common stock to David E. Strauss. The stock option was granted on January 31, 2020 with an exercise price equal to the closing price of the Company’s common stock on such date. One-fourth of the shares subject to the stock option will vest on the one-year anniversary of Mr. Strauss’ start date and the remainder of the shares will vest in a series of 36 successive equal monthly installments thereafter. The stock option is subject to the terms and conditions of the Company's 2019 Equity Incentive Plan and a stock option agreement covering the grant.

Bellicum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

HOUSTON, Jan.  24, 2020  (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today presented new Phase 1 translational results for BPX-601 at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco. The poster titled “ Tumor Infiltration and Cytokine Biomarkers of Prostate Stem Cell Antigen (PSCA)-Directed GoCAR-T Cells in Patients with Advanced Pancreatic Tumors ” presented new data from a cohort treated with BPX-601 and a single dose of rimiducid that showed immunomodulation in both the periphery and tumor microenvironment and provided additional insights into surrogate biomarkers of iMC-mediated GoCAR-T® activity.

Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium

Houston manufacturing facility and portions of Bellicum’s Technical Operations and Quality staff to be acquired by MD Anderson

Bellicum Pharmaceuticals Enters into Asset Purchase and Master Services Agreements with MD Anderson

Bellicum’s proprietary technology licensed for use in CD19 CAR NK program Bellicum’s proprietary technology licensed for use in CD19 CAR NK program

Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD Anderson

iMC activation enhances innate NK cell cytotoxicity against tumor cell lines in vitro

Bellicum Pharmaceuticals Presents Encouraging Preclinical Data for GoCAR-NK Cell Program at Society for Immunotherapy of Cancer Annual Meeting

Bellicum Pharmaceuticals, Inc. (BLCM) CEO Rick Fair on Q3 2019 Results - Earnings Call Transcript

Bellicum Pharmaceuticals (BLCM) delivered earnings and revenue surprises of -1.75% and -65.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Bellicum Pharmaceuticals (BLCM) Reports Q3 Loss, Lags Revenue Estimates

Earnings Preview: Bellicum Pharmaceuticals (BLCM) Q3 Earnings Expected to Decline

The stock has gained 20% since Baker Bros. disclosed its stake in the company.

Bellicum: Moving Toward MAA Submission For Rivo-Cel

Bellicum has produced some solid trial data for its lead therapy candidate BPX-501 in pediatric HSCT patients.

Bellicum: Strong Trial Data, Poor Share Price, Dire Financials

HOUSTON, Aug.  28, 2019  (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that senior management will participate in three upcoming healthcare investor conferences.

Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September

Closing of $57.5 Million Public Offering of Preferred Stock and Warrants and Receipt of $12.1 Million Option Fee Related to Private Placement of up to $70.0 Million of Preferred Stock and Warrants  Closing of $57.5 Million Public Offering of Preferred Stock and Warrants and Receipt of $12.1 Million Option Fee Related to Private Placement of up to $70.0 Million of Preferred Stock and Warrants

Bellicum Pharmaceuticals Announces Aggregate Gross Proceeds of $69.6 Million from $139.6 Million Public Offering and Private Placement

Bellicum Pharmaceuticals (BLCM) delivered earnings and revenue surprises of -7.41% and 497.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Bellicum Pharmaceuticals (BLCM) Reports Q2 Loss, Tops Revenue Estimates

Bellicum Pharmaceuticals (BLCM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Bellicum recently publicized Rivo-cel hit the primary endpoint of event-free survival rate at 180 days of 90.9% in their BP-004 European registrational study.

Bellicum: Ready To Transition Into A Commercial Stage Company

Bellicum Pharmaceuticals recently reported promising data for BPX-601 at ASCO. The company's GoCAR-T program is taking aim at solid tumors and could be a leading therapy if approved.

News for Bellicum Pharmaceuticals Stock (BLCM)